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AbsTRACT
Objective To provide a consistently updated overview 
of the comparative effectiveness of treatments for 
Achilles tendinopathy.
Design Living systematic review and network meta- 
analysis.
Data sources Multiple databases including grey 
literature sources were searched up to February 2019.
study eligibility criteria Randomised controlled 
trials examining the effectiveness of any treatment in 
patients with both insertional and/or midportion Achilles 
tendinopathy. We excluded trials with 10 or fewer 
participants per treatment arm or trials investigating 
tendon ruptures.
Data extraction and synthesis Reviewers 
independently extracted data and assessed the risk 
of bias. We used the Grading of Recommendations 
Assessment, Development and Evaluation to appraise the 
certainty of evidence.
Primary outcome measure The validated patient- 
reported Victorian Institute of Sport Assessment- Achilles 
questionnaire.
Results 29 trials investigating 42 different treatments 
were included. 22 trials (76%) were at high risk of bias 
and 7 (24%) had some concerns. Most trials included 
patients with midportion tendinopathy (86%). Any 
treatment class seemed superior to wait- and- see for 
midportion Achilles tendinopathy at 3 months (very low 
to low certainty of evidence). At 12 months, exercise 
therapy, exercise+injection therapy and exercise+night 
splint therapy were all comparable with injection therapy 
for midportion tendinopathy (very low to low certainty). 
No network meta- analysis could be performed for 
insertional Achilles tendinopathy.
summary/conclusion In our living network meta- 
analysis no trials were at low risk of bias and there 
was large uncertainty in the comparative estimates. For 
midportion Achilles tendinopathy, wait- and- see is not 
recommended as all active treatments seemed superior 
at 3- month follow- up. There seems to be no clinically 
relevant difference in effectiveness between different 
active treatments at either 3- month or 12- month 
follow- up. As exercise therapy is easy to prescribe, can 
be of low cost and has few harms, clinicians could 





The incidence of Achilles tendinopathy is 2–3 per 
1000 patients in general medicine practice, and its 
lifetime cumulative incidence can even increase to 
more than 50% in specific active populations (eg, 
runners).1 2 Achilles tendinopathy is an overload 
injury that is diagnosed clinically, and can affect the 
distal insertion or the midportion of the tendon.3 4 
Managing tendinopathy is challenging. Patients can 
expect their symptoms to improve between 3 and 
12 months after commencing treatment, but not 
beyond 12 months.5 Chronic symptoms persist in 
approximately a quarter of patients 10 years after 
treatment, and tendinopathy impairs both quality 
of life and physical activity.5 6
Wait- and- see, exercise therapy, injections, shock-
wave therapy, orthosis, medication and surgery are 
the main treatment options offered to patients with 
Achilles tendinopathy.7–14 Most patients receive 
multiple treatments over time, thereby impacting on 
healthcare consumption.15 Trials and conventional 
meta- analysis do not directly assess the relative 
effectiveness of all available treatments, challenging 
patients and clinicians when they make treatment 
decisions. Network meta- analysis (NMA) allows 
the simultaneous comparison of the effectiveness of 
all treatments and can rank treatments from most to 
least effective.16 17 As no comprehensive NMA of all 
treatment options for Achilles tendinopathy exists, 
our aim was to evaluate the comparative effective-
ness of all available treatments for Achilles tendi-




Our living systematic review with NMA was 
prospectively registered on PROSPERO (Interna-
tional Prospective Register of Systematic Reviews) 
and published in an open repository.18 We followed 
the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) guideline, 
the Meta- Analysis of Observational Studies in 
Epidemiology guideline, and the PRISMA- NMA 
extension for reporting NMA.19–21
Administration and update of the living 
systematic review
This systematic review with NMA is part of the 
Dutch multidisciplinary guideline for Achilles 
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Table 1 Assignment of treatments to classes
Treatments studies Classes
Placebo injection+eccentric exercises (high- dose) Bell 2013,33 Boesen 2017,35 de Jonge 201137 Exercise therapy+placebo injection
Autologous blood injection+eccentric exercises (high- dose) Bell 2013,33 Pearson 201243 Exercise+injection therapy
High- volume injection+eccentric exercises (high- dose) Boesen 201735 Exercise+injection therapy
Platelet- rich plasma injection+eccentric exercises (high- dose) Boesen 2017,35 de Jonge 201137 Exercise+injection therapy
Eccentric exercises (high- dose) Pearson 2012,43 Beyer 2015,34 de Jonge 2010,36 
Silbernagel 2007,48 Yelland 2011,52 Rompe 2007,46 
Rompe 2009,46 Zhang 2013,53 Balius 2016,32 
Stevens 201449
Exercise therapy
Heavy slow resistance exercises Beyer 201534 Exercise therapy
Night splint+eccentric exercises (high- dose) de Jonge 201036 Exercise+night splint therapy
Continued sports activity+eccentric exercises (high- dose) Silbernagel 200748 Exercise therapy
Prolotherapy injections Yelland 201152 Injection therapy
Prolotherapy injections+eccentric exercises (high- dose) Yelland 201152 Exercise+injection therapy
Shockwave therapy Rompe 200746 Shockwave therapy
Wait- and- see Rompe 200746 Wait- and- see
Shockwave therapy+eccentric exercises (high- dose) Rompe 200945 Exercise+shockwave therapy
Acupuncture treatment Zhang 201353 Acupuncture therapy
Mucopolysaccharides supplement+eccentric exercises (high- dose) Balius 201632 Exercise+mucopolysaccharides supplement 
therapy
Mucopolysaccharides supplement+passive stretching Balius 201632 Exercise+mucopolysaccharides supplement 
therapy
Eccentric exercises as tolerated Stevens 201449 Exercise therapy
tendinopathy. As we (1) plan to update the search and review 
process every 5 years as part of the guideline revision process, 
and (2) perform annual screening to identify new data that may 
alter the conclusions and recommendations,18 we defined this 
as a ‘living’ systematic review with NMA. A living systematic 
review’s main advantage is that it assumes that new knowledge 
will appear and allow improvements in clinical decision- making. 
As we already have a structured protocol and database for this 
systematic review, we will be able to answer future research 
questions quickly and promote faster translation of new scien-
tific evidence into clinical practice.
Patient involvement
To determine clinically relevant outcomes, we performed a pilot 
round of focus interviews with consecutive patients suffering 
from chronic midportion Achilles tendinopathy (n=9) who were 
participating in a randomised clinical trial (NCT02996409), and 
administered a survey to patients identified through the Dutch 
national patient federation (n=97).17 The results are presented 
in online supplementary web appendix 1. We also consid-
ered recently defined core domains for tendinopathies from 
an international consensus involving patients and healthcare 
providers.22 Based on these data, we decided to evaluate clinical 
outcome with the validated and disease- specific Victorian Insti-
tute of Sport Assessment- Achilles (VISA- A) score as the primary 
outcome.18 23
Outcome measures
The VISA- A score quantifies pain and activity level and can 
range from 0 to 100; a score of 100 indicates no pain with full 
activity level, while a score of 0 indicates severely limited activity 
levels and severe levels of pain. The minimal important differ-
ence (MID) for the VISA- A score is 15 points.24 Return to sports 
activities was the secondary outcome. We assessed outcomes at 
3, 6 and 12 months.
Eligibility criteria
Trials were eligible if they investigated the effectiveness of any 
treatment in adults (≥18 years) with Achilles tendinopathy, 
using the outcome measures VISA- A questionnaire and/or return 
to sports activities. Populations with midportion tendinop-
athy, insertional tendinopathy or a combination of both were 
included. Achilles tendinopathy must have been diagnosed based 
on clinical findings (eg, local pain reproduced on clinical exam-
ination).25 Imaging to confirm the diagnosis was not an inclusion 
criterion. Trials including athletes and/or inactive patients were 
eligible. There were no language restrictions.
Any treatment, control treatment, placebo, wait- and- see or no 
treatment group studied in a trial was eligible for inclusion. We 
predefined a number of treatment classes, based on the assump-
tion that some treatments have a similar effect due to a compa-
rable working mechanism.18 Table 1 shows the treatments that 
are subdivided into treatment classes.
We excluded trials with (1) 10 or fewer participants per study 
arm, (2) an inadequate control group (eg, the use of the contra-
lateral Achilles tendon), (3) a population with full- thickness 
ruptures of the Achilles tendon, and (4) animal or in vitro studies.
Literature search strategy and information source
We developed a sensitive search strategy for multiple databases 
with the assistance of a medical librarian (online supplemen-
tary web appendix 2). The following databases were searched 
for published and unpublished trials up to 21 February 2019: 
Embase, MEDLINE Ovid, Web of Science, Cochrane CENTRAL, 
CINAHL EBSCOhost, SPORTDiscus EBSCOhost, AMED 
EBSCOhost, WHO ICTRP,  ClinicalTrials. gov,  WorldCat. org, 
OpenGrey and Google Scholar. We used the validated Cochrane 
search filter ‘Embase search strategy for finding randomised 
clinical trials in Embase’, and modified this for all conventional 
databases.26 We screened the reference lists of all included publi-
cations for potentially eligible trials.
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study selection and data extraction
Titles and abstracts were screened by two independent reviewers 
(ACV and RJ- V) after duplicate removal. Disagreements were 
resolved by consensus. Two reviewers independently applied 
eligibility criteria to the full text reports. Disagreements were 
resolved by a third reviewer (AW). In case of unpublished 
records, authors were contacted for data availability. We 
uploaded all trials to Covidence (Veritas Health Innovation, 
Melbourne, Australia).
Data were extracted independently by two reviewers (ACV 
plus one of AW, CA or RJ- V) using standardised extraction forms 
adapted from the Cochrane Collaboration.26 Disagreements 
were resolved by consensus, or a fifth reviewer (MW) in case 
of persistent disagreement. We extracted publication and trial 
details, population characteristics, eligibility criteria, treatment 
details, relevant outcome information, details of analysis, and 
study authors’ key conclusions. If there were multiple time 
points available within a study, and these were equally close to 
the time point being synthesised across trials, we extracted the 
outcome of the latest follow- up for analysis.18
Risk of bias assessment
We used the Risk of Bias 2 tool to assess risk of bias for each 
trial outcome.27 We assessed risk of bias on the basis of ‘assign-
ment to intervention’ for all five domains: (1) randomisation 
process, (2) deviations from intended interventions, (3) missing 
outcome data, (4) outcome measurement and (5) selection of 
the reported result. An overall risk of bias judgement was made 
for each outcome and each time point as either ‘low risk’, ‘some 
concerns’ or ‘high risk’ of bias.27 28
The assessment was performed independently by two reviewers 
(ACV plus one of MW, CLA, AW or RJ- V). The reviewers did not 
perform risk of bias assessment or data extraction for publica-
tions in which they were involved as author. Disagreements were 
resolved via consensus or by a third reviewer (MW or AW) if 
necessary.
Data synthesis and statistical methods
We constructed network plots using Stata V.15 to visualise all 
head- to- head comparisons. Eccentric exercises were labelled 
as high- dose (daily) or low- dose (less than once a day). We 
planned a time course analysis for the VISA- A score; however, 
insufficient data precluded the analysis.18 Instead, we modelled 
networks for the primary and secondary outcomes at 3 months, 
6 months and 12 months, where possible. Four reviewers (ACV, 
MW, AW and R- JV) labelled the treatments and assigned them to 
categories (classes) (see table 1). We assessed the assumption of 
exchangeability required for NMA before commencing the anal-
yses. We appraised clinical homogeneity by tabulating study and 
population characteristics and inspecting them for differences in 
effect modifiers.
Treatment- level and class- level models were fitted in a Bayesian 
framework using Markov chain Monte Carlo simulations in 
WinBUGS (V.1.4; Medical Research Council, UK, and Impe-
rial College of Science, Technology and Medicine, University 
of Cambridge, UK).17 29 Continuous outcomes are presented as 
mean difference, with their 95% credible intervals. We reported 
the mean, median and 95% credible intervals for the ranking of 
each treatment or class to estimate the likelihood of individual 
treatments being superior to other treatments, and interpreted 
the primary outcome results in light of the MID.
For both treatment- level and class- level models, we fitted 
fixed and random effects models, and compared model fit using 
the deviance information criterion and posterior mean residual 
deviance.17 Lower deviances depict a better model fit. For the 
class- level models we attempted to fit a hierarchical model 
where treatment effects were assumed to be similar within class, 
but due to insufficient data we were only able to fit a fixed class 
effect model where all treatments were assumed to have the 
same effect within class.17
We assessed statistical heterogeneity by inspecting the between- 
trial SD and comparing the fit of the fixed and random effects 
models.17 We planned to explore sources of statistical heteroge-
neity if there were 10 or more trials available per comparison. 
In the presence of evidence from direct and indirect compar-
isons, it is important to assess whether the direct and indirect 
evidence is consistent.30 We assessed the consistency assumption 
for each network by comparing model fit between the NMA 
model and an unrelated mean effects model that relaxes the 
consistency assumption.30 We planned to assess small study bias 
using comparison- adjusted funnel plots if 10 or more trials were 
available for one comparison.
Certainty of evidence
We used the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) for NMAs to appraise the 
certainty of evidence.31 Evidence from each comparison was 
appraised for direct and indirect comparisons, and for the 
combined evidence, where applicable. Evidence could be of 
‘high certainty’, ‘moderate certainty’, ‘low certainty’ or ‘very low 
certainty’. All ratings started at the level of ‘high certainty’. Two 
authors (ACV and MW) independently rated the evidence down 
on the basis of risk of bias, inconsistency, indirectness, impre-
cision and publication bias. Inconsistency in GRADE involves 
heterogeneity across trials and is not related to inconsistency 
in the network. We rated the overall body of evidence in the 
network to indicate the strength of the NMA recommendations.
REsuLTs
We identified 5,154 potentially relevant publications, of which 
170 articles were screened in the full- text analysis. Twenty- nine 
trials (n=1,640 patients) met our eligibility criteria and were 
included (figure 1).32–60 Online supplementary web appendix 
3 lists the 14 unpublished trials and the 3 trials awaiting 
classification.
Characteristics of the included trials
Forty- two treatments were investigated in 29 trials. Sixty- five 
treatment arms were included in the trials, and 40 of these 
included exercise therapies. There were 180 treatment compar-
isons in the NMAs. The majority of trials (86%) investigated 
midportion Achilles tendinopathy, one investigated insertional 
Achilles tendinopathy and three trials did not specify the loca-
tion of Achilles tendinopathy. Twenty- five trials evaluated clinical 
outcome using the VISA- A score and six trials reported return to 
sports activities. Sample sizes ranged from 12 to 117 per treat-
ment arm (median 20 patients, IQR 16–27). Follow- up duration 
ranged from 1 to 52 weeks (median 27 weeks, IQR 12–52).
The baseline characteristics of patients and all trial charac-
teristics are shown in online supplementary web appendices 4 
and 5. Study populations reflect clinical practice with equal sex 
distribution, participants in their 40s and slightly overweight. 
Three- quarters of the included participants were active indi-
viduals. Participants typically had symptoms for nearly 2 years 
prior to treatment; approximately 20% had bilateral symptoms. 
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Figure 2 Network plots for treatment classes on the VISA- A score 
at 3 and 12 months in patients with midportion Achilles tendinopathy. 
The size of the dots is proportional to the number of participants who 
received the treatment, respectively. Blue numbers indicate the number 
of trials the classes were compared in. Note that intraclass comparisons 
are not included in the plot (eg, eccentric exercises vs heavy slow 
resistance exercises); all treatment comparisons can be found in online 
supplementary appendix 9. (A) VISA- A score at 3 months. (B) VISA- A 
score at 12 months. VISA- A, Victorian Institute of Sport Assessment- 
Achilles.
Figure 1 PRISMA flow diagram of the study selection process. IPD, 
individual patient data; LPLV, last patient last visit; PRISMA, preferred 
reporting items for systematic reviews and meta- analyses.
The severity of symptoms measured with the VISA- A score was 
usually between 40 and 60 points.
Risk of bias and certainty of evidence
Twenty- two trials (76%) were at high risk of bias (online supple-
mentary web appendix 6). We had some concerns about bias in 
seven trials (24%). No trials were at low risk of bias. In studies 
that used both the VISA- A score and return to sport as outcome 
measures, there was no difference in risk of bias between the 
outcomes. In 48% of the trials, outcome measurement was a 
source of bias. All other sources of bias were also commonly 
judged as high risk: the randomisation procedure (21%), devi-
ations from the intended intervention (28%), missing outcome 
data (28%) and selection of reported results (24%).
Certainty of evidence for all comparisons was low to very low, 
except for autologous blood+eccentric exercise therapy versus 
placebo injection+eccentric exercise therapy, for which there 
was moderate certainty of evidence (online supplementary web 
appendix 7). The main reasons to rate down the certainty of 
evidence were study limitations (n=180, 100%) and imprecision 
(n=158, 88%). We did not rate down for inconsistency, indirect-
ness or publication bias. Only two treatment comparisons were 
studied in multiple (ie, 2) trials (ie, platelet- rich plasma injec-
tion+eccentric exercise therapy vs placebo injection+eccentric 
exercise therapy, and laser+eccentric exercise therapy vs placebo 
laser+eccentric exercise therapy). Where this was the case, esti-
mates and credible intervals had substantial overlap. Popula-
tions, treatments and outcome measures followed those used in 
clinical practice; hence, there was no indication of indirectness 
in the evidence. We did not assess publication bias because there 
were fewer than 10 trials available for each of the comparisons.
network meta-analyses
Figure 2A,B shows direct treatment class comparisons in the 
field of midportion Achilles tendinopathy for VISA- A score. 
Model fit statistics are reported in online supplementary web 
appendix 8. Ten classes were included in the network analyses. 
None of the networks included evidence from both direct and 
indirect comparisons, so the consistency assumption for NMA 
could not be checked. Figure 3 shows the comparative treat-
ment class effects on the VISA- A score at 3 months (figure 3A) 
and 12 months (figure 3B). Figures 4 and 5 show the treatment 
class rankings for 3 and 12 months. No class analyses could 
be performed for the VISA- A score at 6 months and return to 
sports activities at 6 months (only time point in NMA) due to 
insufficient evidence (online supplementary web appendix 8). 
Treatment effect NMAs for VISA- A and return to sports activi-
ties are presented in online supplementary web appendix 9. No 
NMA could be performed for insertional Achilles tendinopathy. 
Studies that could not be included in the NMA are presented in 
online supplementary web appendix 10.
Comparative treatment class effectiveness on the primary 
outcome (VIsA-A score)
VISA-A score at 3 months
Seventeen treatments, studied in 13 randomised controlled 
trials (RCTs), were assigned to 10 classes. Any treatment 
seemed superior to wait- and- see: exercise+placebo injec-
tion therapy (mean difference 19 points, 95% CrI −3 to 34 
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Figure 3 Comparative treatment class effects expressed with a mean 
difference for the VISA- A score at 3 months (A) and at 12 months (B) in 
patients with midportion Achilles tendinopathy. Mean differences on the 
VISA- A score with their 95% credible intervals from the network meta- 
analysis. For any cell, a negative mean difference favours the upper- left 
treatment, and a positive mean difference favours the lower- right 
treatment. Comparative treatment class effect differences are shown in 
bold. VISA- A, Victorian Institute of Sport Assessment- Achilles.
Figure 4 Treatment class rankings from the network meta- analysis 
for the VISA- A score at 3 months in patients with midportion Achilles 
tendinopathy. The asterix indicates that the 95% credible interval was 
rank 10 to 10 for wait- and- see therapy. MPS, mucopolysaccharides 
supplement; VISA- A, Victorian Institute of Sport Assessment- Achilles.
Figure 5 Treatment class rankings from the network meta- analysis 
for the VISA- A score at 12 months in patients with midportion Achilles 
tendinopathy. VISA- A, Victorian Institute of Sport Assessment- Achilles.
points), injection therapy (23 points, 8 to 38 points), exercise 
therapy (20 points, 11 to 30 points), shockwave therapy (15 
points, 6 to 24 points), exercise+injection therapy (22 points, 
7 to 36 points), exercise+shockwave therapy (34 points, 21 to 
47 points), exercise+night splint therapy (21 points, 4 to 39 
points), acupuncture therapy (35 points, 25 to 45 points) and 
mucopolysaccharides supplement+exercise therapy (28 points, 
14 to 41 points) (figure 3A).
Acupuncture therapy seemed superior to placebo injection 
therapy (16 points, 4 to 30 points), injection therapy (13 points, 
0 to 25 points), exercise therapy (15 points, 11 to 19 points), 
shockwave therapy (20 points, 9 to 31 points), exercise+injec-
tion therapy (13 points, 2 to 25 points), exercise+night splint 
therapy (14 points, −1 to 30 points) and mucopolysaccharides 
supplement+exercise therapy (7 points, −3 to 19 points), but 
not to exercise+shockwave therapy (1 point, −9 to 11 points).
Exercise+shockwave therapy seemed superior to placebo 
injection therapy (15 points, 1 to 31 points), injection therapy 
(11 points, −4 to 26 points), exercise therapy (14 points, 5 to 
23 points), shockwave therapy alone (19 points, 5 to 32 points), 
exercise+injection therapy (12 points, −2 to 27 points) and 
exercise+night splint therapy (13 points, −4 to 30 points), but 
not to acupuncture therapy (−1 point, −11 to 9 points) and 
mucopolysaccharides supplement+exercise therapy (6 points, 
−7 to 20 points).
VISA-A score at 12 months
At 12 months, six treatments, studied in four RCTs, were 
assigned to four treatment classes and compared in a network 
model. Exercise therapy (−5 points, −19 to 9 points), exer-
cise+injection therapy (2 points, −10 to 13 points) and exer-
cise+night splint therapy (3 points, −16 to 22 points) were all 
comparable with injection therapy (figure 3B).
Treatment class rankings
According to the NMA rankings, acupuncture therapy seemed 
the best treatment at 3 months (mean ranking 1.56, median 
ranking 1, median’s 95% CrI 1 to 3), and exercise+shockwave 
therapy seemed second best (mean ranking 1.98, median ranking 
2, median’s 95% CrI 1 to 5). At 12 months, injection therapy 
(mean ranking 2.47, median ranking 2, median’s 95% CrI 1 to 
4), exercise therapy (mean ranking 3.51, median ranking 4, medi-
an’s 95% CrI 2 to 4), exercise+injection therapy (mean ranking 
2.03, median ranking 2, median’s 95% CrI 1 to 4) and exer-
cise+night splint therapy (mean ranking 1.99, median ranking 2, 
median’s 95% CrI 1 to 4) had similar rankings (figures 4 and 5).
Comparative treatment class effectiveness on the secondary 
outcome (return to sports activities)
No class analyses could be performed for return to sports activ-
ities at 6 months (only time point for NMA) due to insufficient 
evidence. The results of the treatment- level analyses for return 
to sports activities at 6 months are presented in online supple-
mentary web appendix 9.
DIsCussIOn
In this living systematic review and NMA, none of the trials were 
at low risk of bias, and all evaluated treatments had large uncer-
tainty in the estimates. From a myriad of treatments for midpor-
tion Achilles tendinopathy, active treatment classes seem to have 
clinically meaningful benefits (mean difference exceeded VISA- A 
MID of 15 points) at 3 months compared with wait- and- see.24 
For two classes (acupuncture therapy, and shockwave therapy 
combined with exercise therapy), the credible intervals exceeded 
the MID of 15 points. However, these results were based on 
two small trials (64 and 68 included patients, respectively) at 
high risk of bias. There were no estimates for effectiveness of 
wait- and- see at 12 months. The effectiveness of most active 
treatments in the long term is uncertain. At 12 months, there 
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was no difference between exercise therapy, injection therapies 
and combined therapies.
Clinical implications
Based on the findings in this study, we advise against recom-
mending wait- and- see therapy as a treatment strategy. Active 
treatments had overlapping comparative effects, leaving uncer-
tainty about which treatment is best for Achilles tendinopathy. 
Shared decision- making plays an important role in managing 
Achilles tendinopathy. Safety profile, treatment availability 
and costs should be considered in this clinical decision- making 
process. Calf- muscle exercise therapy is easy to prescribe because 
it is easy to instruct, can be cheap, is available everywhere and 
has a low risk of harm.14 61
The preinjury activity level could play an important role in 
the response to treatments such as exercise therapy as this will 
possibly influence the load that can be applied to the tendon. 
There is currently no tool available to distinguish sedentary 
from athletic patients, and people define this differently. When 
a patient is considered to be sedentary, the VISA- A score could 
be less sensitive to changes as 40% of the score can be obtained 
from sporting activities.23 Therefore, a novel modified version of 
the existing VISA- A questionnaire is currently being developed 
to evaluate treatment response in sedentary individuals.62 In two 
trials, lower baseline VISA- A score was associated with a greater 
increase in VISA- A score.37 48 This is most likely explained by 
regression to the mean (outliers will tend to move towards 
the mean score). Furthermore, physical activity level was not 
a prognostic factor for change in VISA- A score in the trials 
that attempted to measure physical activity.33 More research is 
needed to determine whether athletic and sedentary patients 
should be considered separate patient groups.
strengths and weaknesses in relation to other studies
The uncertainty around the effectiveness for specific treat-
ments has previously been described in Achilles tendinop-
athy. Most recent meta- analyses on treatment effectiveness for 
Achilles tendinopathy did not find superiority of a single treat-
ment.8 10 63–65 All other systematic reviews included randomised 
clinical trials or quasi- randomised controlled clinical trials and 
made strong to weak recommendations in favour of exercise 
therapy,8 platelet- rich plasma65 or against platelet- rich plasma10 
or splinting8 single therapies. Our NMA results conflict with a 
recent systematic review with head- to- head meta- analysis where 
prolotherapy and sclerotherapy were superior to other treat-
ments.13 Differences in study selection criteria (case series were 
also included vs only randomised clinical trials in our NMA) and 
outcome measure selection (eg, general Visual Analogue Scale vs 
a validated patient- reported outcome measure in our NMA) may 
explain the discrepancy.
unanswered questions and future research
As uncertainty around treatment effectiveness remains, future 
trials should be adequately powered and designed. Universally 
agreed diagnostic criteria for both insertional and midportion 
Achilles tendinopathy are needed to prevent heterogeneity in 
included participants. More trials investigating treatment effects 
for insertional Achilles tendinopathy are warranted. New trials 
should include exercise therapy as a stand- alone comparator 
with long- term (≥12 months) follow- up. This would facili-
tate assessment of the comparative effectiveness of new treat-
ments in the network. Based on our findings it is not ethical 
to perform new studies using wait- and- see as a treatment arm. 
The role of patient education has never been explored, but 
should be further assessed. Trialists must include measures from 
the core outcome set for tendinopathy (patient overall rating, 
participation, pain on activity/loading, disability, function, phys-
ical function capacity, quality of life, psychology and pain over 
a specified timeframe).22 We identified eight ongoing trials on 
the effectiveness of multiple treatments for Achilles tendinop-
athy. We aim to perform horizon scanning annually to screen for 
recently published trials. In case of relevant trials, we will update 
the analyses and publish the results when there are important 
changes that affect clinical care. We plan to update this ‘living’ 
systematic review and NMA at least every 5 years as part of the 
Dutch national guideline revision process.
strengths and limitations
We compared treatments in an NMA despite some of these 
treatments having never been compared head- to- head in trials. 
Our living NMA will be updated at least every 5 years, which 
allows for a contemporary evidence synthesis for clinical prac-
tice.66 67 The protocol was registered prospectively and patients 
were involved in selecting outcomes most relevant to them in 
the design phase.
The small sample sizes and bias in the included trials limit 
our conclusions.68 Many of the investigated treatments were 
not connected to the network, which hampered assessing the 
comparative effectiveness of all available treatments. Sources of 
heterogeneity could not be investigated as there were less than 
the required 10 trials per comparison. None of the comparisons 
in the networks had both direct and indirect evidence and so we 
could not check the consistency.17
Treatment outcomes may be different on the basis of some 
patient characteristics and previous Achilles tendinopathy treat-
ment. For example, a sedentary population may respond to exer-
cise treatment differently compared with an athletic population. 
Other effect modifiers may be unilateral/bilateral symptoms, 
duration of symptoms and type/number of previous treatments. 
However, to the best of our knowledge, there is presently no 
evidence supporting any of these factors as treatment effect 
modifiers. The limited amount of study- level data precluded 
investigating effect modification. This may be possible in the 
future using pooled individual patient data.
We excluded many trials because they did not use commonly 
accepted and validated outcomes in the field of Achilles tend-
inopathy.69 It is unclear whether our NMA results apply to all 
patients with Achilles tendinopathy because we only included 
one trial with patients with insertional Achilles tendinopathy. We 
planned a time course analysis for the VISA- A score, as outcomes 
within the first year are of equal importance. Due to a lack of 
data, we were not able to perform this analysis and, in accor-
dance with our protocol, we modelled outcomes for 3 months, 6 
months and 12 months instead.
We planned threshold analysis as a quantitative means to assess 
the robustness of NMA recommendations to potential limitations 
in the evidence. We were unable to use this approach because of 
substantial overlap in credible intervals from the NMA. Due to 
overlap in the intervals, no recommendations could be made, 
which is a fundamental prerequisite to performing a valid 
threshold analysis. To comply with our protocol, we report 
threshold results in online supplementary web appendix 11, 
but chose to use GRADE to interpret the evidence. We were 
not able to evaluate small study bias due to too low number of 
trials. We found three completed trials in trial registers; two are 
under review, and the publication status of one trial is unknown. 
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Therefore, it seems unlikely that, in an era of prospective trial 
registrations, significant publication bias is present in the field of 
Achilles tendinopathy.
COnCLusIOn
Our living NMA of 29 RCTs on Achilles tendinopathy included 
42 different treatments. No trials were at low risk of bias, most 
had only short follow- up, and there was large uncertainty 
in the comparative estimates. For midportion Achilles tend-
inopathy, active treatments seem superior to wait- and- see at 
3- month follow- up. There was no evidence of a clinically rele-
vant difference in effectiveness between different active treat-
ments at 3- month and 12- month follow- up. Calf- muscle exercise 
therapy is easy to prescribe in practice, is widely available, and 
is regarded as safe and cheap. Consequently, clinicians should 
consider starting this as initial treatment.
What is already known
 ► Achilles tendinopathy is a common, persisting condition 
where one in four patients still has symptoms after 10 years.
 ► Achilles tendinopathy can be disabling and impacts on quality 
of life.
 ► Many patients receive multiple treatments, which represents 
high healthcare consumption.
 ► The comparative effectiveness of treatments for Achilles 
tendinopathy is currently unknown.
What are the new findings
 ► In our living network meta- analysis of randomised controlled 
trials of patients with Achilles tendinopathy, wait- and- see is 
not recommended as all active treatments were found to be 
superior to it.
 ► Given the large uncertainty in comparative estimates and 
risk of bias in the studies, no specific treatment can be 
recommended over another.
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